



## Clinical trial results:

### Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

#### Summary

EudraCT number	2019-003352-37
Trial protocol	FR DK GB DE ES AT PL IT
Global end of trial date	01 November 2024

#### Results information

Result version number	v1 (current)
This version publication date	30 August 2025
First version publication date	30 August 2025

#### Trial information

##### Trial identification

Sponsor protocol code	ALXN1210-NMO-307
-----------------------	------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04201262
WHO universal trial number (UTN)	-
Other trial identifiers	Other Identifier: Alexion Pharmaceuticals: CHAMPION-NMO-307

Notes:

#### Sponsors

Sponsor organisation name	Alexion Pharmaceuticals, Inc.
Sponsor organisation address	121 Seaport Boulevard, Boston, MA, United States, 02210
Public contact	European Clinical Trial Information, Alexion Pharmaceuticals, Inc., +35 3874162507, clinicaltrials.eu@alexion.com
Scientific contact	European Clinical Trial Information, Alexion Pharmaceuticals, Inc., +35 3874162507, clinicaltrials.eu@alexion.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 November 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	01 November 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the effect of ravulizumab on adjudicated On-trial Relapses in adult participants with neuromyelitis optica spectrum disorder (NMOSD).

Protection of trial subjects:

This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki, Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice (ICH GCP) Guidelines, and other applicable laws and regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 December 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 1
Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Germany: 7
Country: Number of subjects enrolled	Denmark: 2
Country: Number of subjects enrolled	Spain: 4
Country: Number of subjects enrolled	United Kingdom: 4
Country: Number of subjects enrolled	Hong Kong: 1
Country: Number of subjects enrolled	Croatia: 1
Country: Number of subjects enrolled	Italy: 6
Country: Number of subjects enrolled	Japan: 14
Country: Number of subjects enrolled	Korea, Republic of: 13
Country: Number of subjects enrolled	Poland: 4
Country: Number of subjects enrolled	Russian Federation: 4
Country: Number of subjects enrolled	Türkiye: 4
Country: Number of subjects enrolled	Taiwan: 2
Country: Number of subjects enrolled	United States: 34
Worldwide total number of subjects	105
EEA total number of subjects	24

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	95
From 65 to 84 years	10
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This study utilized the placebo group from Study ECU-NMO-301 (NCT01892345) as an external placebo control.

### Pre-assignment

Screening details:

Participants were screened for eligibility for up to 6 weeks during the Screening Period.

### Period 1

Period 1 title	Primary Treatment Period
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ravulizumab

Arm description:

Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 3 years.

Arm type	Experimental
Investigational medicinal product name	Ravulizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

As specified in the arm description.

<b>Arm title</b>	Placebo (ECU-NMO-301)
------------------	-----------------------

Arm description:

Participants who received eculizumab matching placebo in study ECU-NMO-301.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 1</b>	Ravulizumab	Placebo (ECU-NMO-301)
Started	58	47
Received at Least 1 Dose of Study Drug	58	47
Completed	56	44
Not completed	2	3
Physician decision	1	1
Adverse event, non-fatal	1	2

---

**Period 2**

Period 2 title	Long-term Extension Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

<b>Arm title</b>	Ravulizumab
------------------	-------------

Arm description:

Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 3 years.

Arm type	Experimental
Investigational medicinal product name	Ravulizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

As specified in the arm description.

<b>Number of subjects in period 2<sup>[1]</sup></b>	Ravulizumab
Started	56
Received at Least 1 Dose of Study Drug	56
Completed	55
Not completed	1
Adverse event, serious fatal	1

---

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Participants who entered the LTE period.

## Baseline characteristics

### Reporting groups

Reporting group title	Ravulizumab
Reporting group description:	
Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 3 years.	
Reporting group title	Placebo (ECU-NMO-301)
Reporting group description:	
Participants who received eculizumab matching placebo in study ECU-NMO-301.	

Reporting group values	Ravulizumab	Placebo (ECU-NMO-301)	Total
Number of subjects	58	47	105
Age Categorical Units: participants			
<=18 years	0	0	0
Between 18 and 65 years	51	44	95
>=65 years	7	3	10
Sex: Female, Male Units: participants			
Female	52	42	94
Male	6	5	11
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	9	3	12
Not Hispanic or Latino	45	41	86
Unknown or Not Reported	4	3	7
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	21	15	36
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	6	8	14
White	29	24	53
More than one race	0	0	0
Unknown or Not Reported	2	0	2

## End points

### End points reporting groups

Reporting group title	Ravulizumab
Reporting group description: Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 3 years.	
Reporting group title	Placebo (ECU-NMO-301)
Reporting group description: Participants who received eculizumab matching placebo in study ECU-NMO-301.	
Reporting group title	Ravulizumab
Reporting group description: Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 3 years.	

### Primary: Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period

End point title	Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period
End point description: An On-trial Relapse was defined as a new onset of neurologic symptoms or worsening of existing neurologic symptoms with an objective change (clinical sign) on neurologic examination that persisted for more than 24 hours as confirmed by the treating physician. An adjudicated On-trial Relapse was defined by the protocol and positively adjudicated by the independent relapse adjudication committee. The full analysis set (FAS) included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).	
End point type	Primary
End point timeframe: Baseline up to 2.25 years (end of the Primary Treatment Period)	

End point values	Ravulizumab	Placebo (ECU-NMO-301)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	47		
Units: participants	0	20		

### Statistical analyses

Statistical analysis title	Ravulizumab vs placebo
Comparison groups	Ravulizumab v Placebo (ECU-NMO-301)

Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.014
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0.103

### Secondary: Adjudicated On-trial Annualized Relapse Rate (ARR) in the Primary Treatment Period

End point title	Adjudicated On-trial Annualized Relapse Rate (ARR) in the Primary Treatment Period
-----------------	--

End point description:

The adjudicated On-trial ARR was computed as the total number of relapses divided by the total number of participant years in the study period. A central independent committee was used to adjudicate all On-trial Relapses as determined by the treating physician. Results reported as adjusted adjudicated On-trial ARR based on a Poisson regression centered on the mean historical ARR in the 24 months prior to screening. 9999 = Since there were no relapses, data could not be estimated. The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 2.25 years (end of the Primary Treatment Period)

End point values	Ravulizumab	Placebo (ECU-NMO-301)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	47		
Units: relapses/year on study				
number (confidence interval 95%)	0.000 (-9999 to 9999)	0.350 (0.199 to 0.616)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period

End point title	Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period
-----------------	---

End point description:

The HAI is a rating scale developed to assess mobility by evaluating the time and degree of assistance



required to walk 25 feet. The scale ranges from 0 to 9, with 0 being the best score (asymptomatic; fully ambulatory with no assistance) and 9 being the worst (restricted to wheelchair; unable to transfer self independently). Clinically important change is conditional on the baseline value: worsening if the baseline HAI is 0 and at least 2 points increase or if the baseline HAI is >0 and at least 1 point increase; improvement if the baseline value is at least 2 and at least 1 point decrease; and stable if baseline is 0 or 1 and a 0- or 1-point increase or decrease or baseline is at least 2 and not change. The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

End point type	Secondary
End point timeframe:	
Baseline up to 2.25 years (end of the Primary Treatment Period)	

End point values	Ravulizumab	Placebo (ECU-NMO-301)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	47		
Units: participants				
Clinical Improvement	4	4		
Stable	52	32		
Clinical Worsening	2	11		

## Statistical analyses

Statistical analysis title	Ravulizumab vs placebo
Statistical analysis description:	
The test of proportional odds was determined from a score test. The proportional odds was evaluated in univariate models.	
Comparison groups	Ravulizumab v Placebo (ECU-NMO-301)
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0122 <sup>[1]</sup>
Method	Univariate models

Notes:

[1] - Proportional Odds p-value

## Secondary: Change From Baseline in European Quality of Life Health 5-dimension Questionnaire (EQ-5D) Index Score at the End of Primary Treatment Period

End point title	Change From Baseline in European Quality of Life Health 5-dimension Questionnaire (EQ-5D) Index Score at the End of Primary Treatment Period
-----------------	--

End point description:

The EQ-5D is a generic, standardized, self-administered instrument that provides a simple, descriptive profile and a single index value for health status. It consists of 2 parts; the EQ-5D descriptive system and the EQ-5D visual analogue scale (VAS). The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score that ranges from less than 0 to 1, with higher scores representing a better health status. The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, up to 2.25 years (end of the Primary Treatment Period)

End point values	Ravulizumab	Placebo (ECU-NMO-301)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	47		
Units: units on a scale				
arithmetic mean (standard deviation)	0.005 ( $\pm$ 0.1522)	-0.043 ( $\pm$ 0.2115)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at the End of Primary Treatment Period

End point title	Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at the End of Primary Treatment Period
-----------------	--

End point description:

The EQ-5D is a generic, standardized, self-administered instrument that provides a simple, descriptive profile and a single index value for health status. It consists of 2 parts; the EQ-5D descriptive system and the EQ-5D visual analogue scale (VAS). The EQ-5D VAS is an overall health state scale where the participant selects a number between 0 to 100 to describe the condition of their health, with 100 being 'The best health state you can imagine' and 0 being 'The worst health state you can imagine'. An increase in score indicates improvement. The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, up to 2.25 years (end of the Primary Treatment Period)

End point values	Ravulizumab	Placebo (ECU-NMO-301)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	47		
Units: units on a scale				
arithmetic mean (standard deviation)	2.6 ( $\pm$ 14.07)	0.6 ( $\pm$ 16.39)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Clinically Important Worsening From Baseline in Expanded Disability Status Scale (EDSS) Score at the End of Primary

## Treatment Period

End point title	Number of Participants With Clinically Important Worsening From Baseline in Expanded Disability Status Scale (EDSS) Score at the End of Primary Treatment Period
-----------------	--

### End point description:

Disease-related disability was measured by the EDSS. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. Clinically important worsening was defined as an increase in EDSS score conditional on the baseline value: If the baseline EDSS was 0 and at least 2-point increase; if the baseline is 1 to 5, and at least 1-point increase; if the baseline is > 5 and at least 0.5 increase. The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline up to 2.25 years (end of the Primary Treatment Period)

End point values	Ravulizumab	Placebo (ECU-NMO-301)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	47		
Units: participants				
No clinically important worsening	52	36		
Clinically important worsening	6	11		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Study Drug Discontinuation in the Primary Treatment Period

End point title	Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Study Drug Discontinuation in the Primary Treatment Period
-----------------	--

### End point description:

An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. TEAEs were AEs with a start date on or after the date of the first dose of study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo).

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline up to 2.25 years (end of the Primary Treatment Period)

End point values	Ravulizumab	Placebo (ECU-NMO-301)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	47		
Units: participants				
Any TEAEs	53	45		
TESAEs	8	26		
TEAEs Leading to Study Drug Discontinuation	1	2		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum Ravulizumab Concentration

End point title	Serum Ravulizumab Concentration <sup>[2]</sup>
-----------------	--

End point description:

Pharmacokinetics/pharmacodynamics (PK/PD) analysis set included participants who received at least 1 dose of study drug and who had at least 1 evaluable PK or PD result. Here, 'Number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed (n)' = participants evaluable at specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Predose and end of infusion (EOI) at Week 26

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data collected and reported for treatment arm only, as pre-specified.

End point values	Ravulizumab			
Subject group type	Reporting group			
Number of subjects analysed	56			
Units: micrograms (µg)/milliliter (mL)				
arithmetic mean (standard deviation)				
Week 26: Predose (n=55)	760.3 (± 202.75)			
Week 26: EOI (n=56)	1836.4 (± 355.39)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Serum Free C5 Concentration at Week 26

End point title	Change From Baseline in Serum Free C5 Concentration at Week 26 <sup>[3]</sup>
-----------------	---

End point description:

The PK/PD analysis set included participants who received at least 1 dose of study drug and who had at least 1 evaluable PK or PD result. Here, 'Number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed (n)' = participants evaluable at specified timepoint.

End point type	Secondary			
End point timeframe:				
Baseline, Week 26 (Predose and EOI)				
Notes:				
[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.				
Justification: Data collected and reported for treatment arm only, as pre-specified.				
<b>End point values</b>	Ravulizumab			
Subject group type	Reporting group			
Number of subjects analysed	55			
Units: µg/mL				
arithmetic mean (standard deviation)				
Change at Week 26: Predose (n=54)	-119.02 (± 42.857)			
Change at Week 26: EOI (n=55)	-119.32 (± 42.512)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period

End point title	Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period <sup>[4]</sup>			
End point description:				
The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Here, 'Number analyzed (n)' = participants evaluable at specified timepoint.				
End point type	Secondary			
End point timeframe:				
Baseline, Weeks 26, 50, 82, and 106				
Notes:				
[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data collected and reported for treatment arm only, as pre-specified.				
End point values	Ravulizumab			
Subject group type	Reporting group			
Number of subjects analysed	58			
Units: participants				
Baseline Positive (n=58)	5			
Week 26 Positive (n=55)	1			
Week 50 Positive (n=52)	0			
Week 82 Positive (n=15)	0			
Week 106 Positive (n=1)	0			
Baseline Negative (n=58)	53			
Week 26 Negative (n=55)	54			
Week 50 Negative (n=52)	52			
Week 82 Negative (n=15)	15			
Week 106 Negative (n=1)	1			

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to approximately 5.5 years

Adverse event reporting additional description:

Safety set, all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was reported for primary analysis results only. Data were collected/reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.1
--------------------	------

### Reporting groups

Reporting group title	Primary Treatment Period: Placebo
-----------------------	-----------------------------------

Reporting group description:

Participants who received eculizumab matching placebo in study ECU-NMO-301.

Reporting group title	Long-Term Extension: Ravulizumab
-----------------------	----------------------------------

Reporting group description:

Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 3 years.

Reporting group title	Primary Treatment Period: Ravulizumab
-----------------------	---------------------------------------

Reporting group description:

Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 3 years.

Serious adverse events	Primary Treatment Period: Placebo	Long-Term Extension: Ravulizumab	Primary Treatment Period: Ravulizumab
Total subjects affected by serious adverse events			
subjects affected / exposed	26 / 47 (55.32%)	9 / 56 (16.07%)	8 / 58 (13.79%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive lobular breast carcinoma			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma			

subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland neoplasm			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Orthostatic hypotension			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Respiratory disorder			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Suicidal ideation			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Rib fracture			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post lumbar puncture syndrome			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial ischaemia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive heart disease			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Myelitis transverse			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuromyelitis optica spectrum disorder			
subjects affected / exposed	16 / 47 (34.04%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 17	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuromyelitis optica pseudo relapse			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Pancytopenia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			

subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Pancreatitis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Meningococcal sepsis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			

subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis meningococcal			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	2 / 2	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			

subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Primary Treatment Period: Placebo	Long-Term Extension: Ravulizumab	Primary Treatment Period: Ravulizumab
Total subjects affected by non-serious adverse events			
subjects affected / exposed	43 / 47 (91.49%)	49 / 56 (87.50%)	53 / 58 (91.38%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm skin			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Skin papilloma			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Uterine leiomyoma			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Anogenital warts			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Basal cell carcinoma			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Colorectal adenoma			

subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Benign soft tissue neoplasm			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Dysplastic naevus			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Orthostatic hypotension			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	3	0	0
Flushing			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Lymphoedema			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	2
Deep vein thrombosis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	2 / 58 (3.45%)
occurrences (all)	2	2	2
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	12	0	1
Chest discomfort			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	2	0	1
Axillary pain			

subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Asthenia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	1	0	2
Chills			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	3 / 58 (5.17%)
occurrences (all)	0	0	5
Swelling face			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	4 / 47 (8.51%)	1 / 56 (1.79%)	5 / 58 (8.62%)
occurrences (all)	5	1	6
Peripheral swelling			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	3	0	1
Pain			
subjects affected / exposed	4 / 47 (8.51%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	7	0	2
Oedema peripheral			
subjects affected / exposed	3 / 47 (6.38%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	3	1	0
Oedema			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	0	0	2
Malaise			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	3 / 58 (5.17%)
occurrences (all)	0	0	3
Injection site reaction			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Influenza like illness			

subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	3	0	2
Induration			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Cyst			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	5 / 47 (10.64%)	1 / 56 (1.79%)	3 / 58 (5.17%)
occurrences (all)	5	1	3
Feeling cold			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Gait disturbance			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Generalised oedema			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Vaccination site pruritus			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Vaccination site pain			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	3 / 58 (5.17%)
occurrences (all)	0	1	3
Immune system disorders			
Allergy to arthropod bite			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Seasonal allergy			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	2	1	0
Social circumstances			
Menopause			



subjects affected / exposed occurrences (all)	1 / 47 (2.13%) 1	0 / 56 (0.00%) 0	0 / 58 (0.00%) 0
Reproductive system and breast disorders			
Menopausal symptoms			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Vulvovaginal pruritus			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Dysmenorrhoea			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Endometrial hyperplasia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Menstruation irregular			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Breast pain			
subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Intermenstrual bleeding			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Lactation insufficiency			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Heavy menstrual bleeding			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Respiratory disorder			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			

subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Sinus disorder			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	6 / 47 (12.77%)	3 / 56 (5.36%)	3 / 58 (5.17%)
occurrences (all)	8	4	3
Dyspnoea			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	1	1	1
Epistaxis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	2
Hiccups			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Rhinitis allergic			
subjects affected / exposed	3 / 47 (6.38%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	3	0	1
Sinus congestion			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Atelectasis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Dysphonia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0

Nasal congestion			
subjects affected / exposed	3 / 47 (6.38%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	3	0	0
Nasal discomfort			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	2	1	0
Productive cough			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Tonsillolith			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Upper-airway cough syndrome			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Catarrh			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Cough variant asthma			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Interstitial lung disease			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Paranasal sinus inflammation			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Pleural thickening			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Pneumothorax			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0

Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	1	0	2
Insomnia			
subjects affected / exposed	4 / 47 (8.51%)	2 / 56 (3.57%)	2 / 58 (3.45%)
occurrences (all)	4	2	2
Depressed mood			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Depression			
subjects affected / exposed	4 / 47 (8.51%)	3 / 56 (5.36%)	1 / 58 (1.72%)
occurrences (all)	5	3	1
Post-traumatic stress disorder			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Suicidal ideation			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Agitation			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Delusion			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Hallucination			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Obsessive-compulsive disorder			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Persistent depressive disorder			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Sleep disorder			

subjects affected / exposed occurrences (all)	2 / 47 (4.26%) 3	0 / 56 (0.00%) 0	0 / 58 (0.00%) 0
Sleep talking subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	0 / 56 (0.00%) 0	1 / 58 (1.72%) 1
Attention deficit hyperactivity disorder subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	1 / 56 (1.79%) 1	0 / 58 (0.00%) 0
Product issues Medical device entrapment subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	1 / 56 (1.79%) 1	0 / 58 (0.00%) 0
Investigations Gardnerella test positive subjects affected / exposed occurrences (all)	1 / 47 (2.13%) 1	0 / 56 (0.00%) 0	0 / 58 (0.00%) 0
Hepatic enzyme increased subjects affected / exposed occurrences (all)	1 / 47 (2.13%) 1	0 / 56 (0.00%) 0	2 / 58 (3.45%) 2
Lymphocyte count decreased subjects affected / exposed occurrences (all)	1 / 47 (2.13%) 1	0 / 56 (0.00%) 0	2 / 58 (3.45%) 2
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	1 / 56 (1.79%) 1	1 / 58 (1.72%) 1
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 47 (2.13%) 1	0 / 56 (0.00%) 0	1 / 58 (1.72%) 1
Haemoglobin decreased subjects affected / exposed occurrences (all)	2 / 47 (4.26%) 2	0 / 56 (0.00%) 0	1 / 58 (1.72%) 1
SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	1 / 56 (1.79%) 1	1 / 58 (1.72%) 1
Urinary occult blood			

subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	2
Blood potassium decreased			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Blood pressure systolic increased			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Bone density decreased			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Cortisol decreased			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Electrocardiogram abnormal			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Neutrophil count decreased			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Weight increased			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
White blood cell count decreased			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	3 / 47 (6.38%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	3	0	0
Antinuclear antibody positive			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Blood glucose increased			

subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Blood urea increased			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Culture cervix positive			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Protein urine present			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Red blood cell sedimentation rate increased			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Blood creatinine decreased			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Head injury			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	3	1	0
Infusion related reaction			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	3 / 58 (5.17%)
occurrences (all)	0	0	6
Alcohol poisoning			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Cartilage injury			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Concussion			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Joint dislocation			

subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Ligament sprain			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	1	1	1
Limb injury			
subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	1 / 58 (1.72%)
occurrences (all)	0	2	1
Muscle strain			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Post lumbar puncture syndrome			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	1	1	1
Rib fracture			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	2	1	1
Skin abrasion			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	3	1	1
Tooth fracture			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Chillblains			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	2 / 47 (4.26%)	2 / 56 (3.57%)	0 / 58 (0.00%)
occurrences (all)	6	2	0
Fall			
subjects affected / exposed	4 / 47 (8.51%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	8	2	0
Fibula fracture			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Foot fracture			



subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Fractured sacrum			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Injury			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Procedural complication			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Skin laceration			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	3	0	0
Stress fracture			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Thermal burn			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Thoracic vertebral fracture			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Wound			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Post procedural contusion			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Immunisation reaction			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	1	0	3
Animal bite			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Ankle fracture			

subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Arthropod bite			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Arthropod sting			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Hand fracture			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Procedural headache			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Pulmonary contusion			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Wound complication			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Foreign body			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Extrasystoles			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Tachycardia			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Bradycardia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0

Pericardial effusion			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Heart failure with preserved ejection fraction			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	6 / 47 (12.77%)	1 / 56 (1.79%)	4 / 58 (6.90%)
occurrences (all)	6	1	4
Headache			
subjects affected / exposed	10 / 47 (21.28%)	5 / 56 (8.93%)	15 / 58 (25.86%)
occurrences (all)	17	6	25
Migraine			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	3 / 58 (5.17%)
occurrences (all)	0	0	4
Paraesthesia			
subjects affected / exposed	3 / 47 (6.38%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	4	0	3
Hypoaesthesia			
subjects affected / exposed	4 / 47 (8.51%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	5	1	1
Memory impairment			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	2
Parosmia			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Presyncope			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Sensory disturbance			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Somnolence			

subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Syncope			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Burning sensation			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Dysgeusia			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Head discomfort			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Mental impairment			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Muscle contractions involuntary			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Muscle spasticity			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Neuralgia			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Post herpetic neuralgia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Uhthoff's phenomenon			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Neuromyelitis optica pseudo relapse			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Facial paralysis			

subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Partial seizures with secondary generalisation			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Tremor			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Migraine with aura			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Lymphadenopathy			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	3 / 58 (5.17%)
occurrences (all)	2	1	3
Anaemia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Iron deficiency anaemia			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Leukopenia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Macrocytosis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Lymphopenia			

subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	1 / 56 (1.79%) 1	0 / 58 (0.00%) 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 47 (2.13%)	3 / 56 (5.36%)	3 / 58 (5.17%)
occurrences (all)	1	3	3
Ear pain			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	3	0	1
Paraesthesia ear			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	2
Eustachian tube dysfunction			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Tinnitus			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Eye disorders			
Conjunctivitis allergic			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Blepharitis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	0	0	2
Eye disorder			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Eye pain			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Ocular discomfort			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Ocular hyperaemia			

subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Vision blurred			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Visual impairment			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Conjunctival haemorrhage			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Photophobia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Retinal degeneration			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Cataract			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Photopsia			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Eyelid ptosis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Dry eye			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	6 / 47 (12.77%)	5 / 56 (8.93%)	3 / 58 (5.17%)
occurrences (all)	14	6	3
Constipation			
subjects affected / exposed	3 / 47 (6.38%)	0 / 56 (0.00%)	4 / 58 (6.90%)
occurrences (all)	3	0	5

Vomiting			
subjects affected / exposed	8 / 47 (17.02%)	1 / 56 (1.79%)	4 / 58 (6.90%)
occurrences (all)	10	1	5
Gastrooesophageal reflux disease			
subjects affected / exposed	3 / 47 (6.38%)	1 / 56 (1.79%)	3 / 58 (5.17%)
occurrences (all)	5	1	4
Nausea			
subjects affected / exposed	12 / 47 (25.53%)	3 / 56 (5.36%)	2 / 58 (3.45%)
occurrences (all)	17	3	2
Abdominal distension			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Alveolar bone resorption			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Anal incontinence			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	2 / 58 (3.45%)
occurrences (all)	1	1	2
Abdominal tenderness			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Food poisoning			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Gastric ulcer			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Periodontal disease			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	2
Stomatitis			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	2	1	3



Abdominal pain			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	3	0	0
Abdominal pain upper			
subjects affected / exposed	3 / 47 (6.38%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	3	0	1
Dyspepsia			
subjects affected / exposed	4 / 47 (8.51%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	4	1	2
Angular cheilitis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Aphthous ulcer			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Colitis microscopic			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Gingival pain			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Intestinal obstruction			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Lip blister			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Mouth ulceration			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Presbyoesophagus			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Toothache			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	2	1	0

Lip pain			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Gastritis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Dysphagia			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Dental caries			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Abdominal pain lower			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Abdominal fat apron			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Faeces soft			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Rectal polyp			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Pancreatic cyst			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Hiatus hernia			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Haematochezia			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Anorectal discomfort			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0

Hepatobiliary disorders			
Hepatic function abnormal			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Hepatic steatosis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Cholecystitis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Cholelithiasis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Acne			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	1	0	2
Alopecia			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	2 / 58 (3.45%)
occurrences (all)	2	1	2
Rash			
subjects affected / exposed	4 / 47 (8.51%)	1 / 56 (1.79%)	2 / 58 (3.45%)
occurrences (all)	4	1	2
Dermatitis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	1	0	2
Dry skin			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	2	0	2
Eczema			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	1	1	1
Erythema			

subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Hyperkeratosis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Ingrowing nail			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	4 / 47 (8.51%)	2 / 56 (3.57%)	1 / 58 (1.72%)
occurrences (all)	8	2	1
Psoriasis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Sensitive skin			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Urticaria			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	2	0	1
Dermatitis allergic			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Dermatitis contact			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	3	0	0
Hyperhidrosis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Petechiae			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Pityriasis rosea			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Purpura			

subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Androgenetic alopecia			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Dyshidrotic eczema			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Pigmentation disorder			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	2 / 58 (3.45%)
occurrences (all)	0	1	2
Acute kidney injury			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Haematuria			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Proteinuria			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Strangury			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	5
Cystitis interstitial			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Glycosuria			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0

Nephrolithiasis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Pollakiuria			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Prerenal failure			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Urethral syndrome			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Urinary incontinence			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Cystitis-like symptom			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Micturition urgency			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Endocrine disorders			
Thyroid cyst			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Thyroid mass			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Musculoskeletal and connective tissue disorders			
Muscle spasms			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	2	1	1
Back pain			
subjects affected / exposed	6 / 47 (12.77%)	2 / 56 (3.57%)	7 / 58 (12.07%)
occurrences (all)	9	3	8
Arthralgia			

subjects affected / exposed	4 / 47 (8.51%)	2 / 56 (3.57%)	6 / 58 (10.34%)
occurrences (all)	9	2	6
Myalgia			
subjects affected / exposed	3 / 47 (6.38%)	0 / 56 (0.00%)	3 / 58 (5.17%)
occurrences (all)	3	0	3
Neck pain			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	2	0	2
Pain in extremity			
subjects affected / exposed	10 / 47 (21.28%)	2 / 56 (3.57%)	2 / 58 (3.45%)
occurrences (all)	11	3	2
Joint swelling			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Limb discomfort			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Musculoskeletal discomfort			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Periarthritis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Rheumatoid arthritis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Flank pain			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Fracture pain			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Intervertebral disc protrusion			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Muscular weakness			

subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Osteonecrosis			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Osteopenia			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Osteoporosis			
subjects affected / exposed	2 / 47 (4.26%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	2	1	0
Synovial disorder			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Pelvic deformity			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Muscle contracture			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	2 / 58 (3.45%)
occurrences (all)	0	2	3
Synovial cyst			
subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Systemic lupus erythematosus			
subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Temporomandibular pain and dysfunction syndrome			
subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Foot deformity			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0



Plantar fasciitis subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	1 / 56 (1.79%) 1	0 / 58 (0.00%) 0
Spinal retrolisthesis subjects affected / exposed occurrences (all)	1 / 47 (2.13%) 1	0 / 56 (0.00%) 0	0 / 58 (0.00%) 0
Infections and infestations			
Laryngitis subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	0 / 56 (0.00%) 0	1 / 58 (1.72%) 1
COVID-19 subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	16 / 56 (28.57%) 16	14 / 58 (24.14%) 15
Urinary tract infection subjects affected / exposed occurrences (all)	9 / 47 (19.15%) 12	6 / 56 (10.71%) 14	6 / 58 (10.34%) 7
Cystitis subjects affected / exposed occurrences (all)	1 / 47 (2.13%) 1	2 / 56 (3.57%) 3	5 / 58 (8.62%) 7
Upper respiratory tract infection subjects affected / exposed occurrences (all)	6 / 47 (12.77%) 10	6 / 56 (10.71%) 12	5 / 58 (8.62%) 5
Nasopharyngitis subjects affected / exposed occurrences (all)	8 / 47 (17.02%) 12	4 / 56 (7.14%) 6	3 / 58 (5.17%) 3
Sinusitis subjects affected / exposed occurrences (all)	0 / 47 (0.00%) 0	2 / 56 (3.57%) 2	3 / 58 (5.17%) 3
Conjunctivitis subjects affected / exposed occurrences (all)	4 / 47 (8.51%) 8	0 / 56 (0.00%) 0	2 / 58 (3.45%) 2
Oral herpes subjects affected / exposed occurrences (all)	2 / 47 (4.26%) 2	4 / 56 (7.14%) 6	3 / 58 (5.17%) 3
Periodontitis			

subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	0	0	2
Bronchitis			
subjects affected / exposed	1 / 47 (2.13%)	2 / 56 (3.57%)	1 / 58 (1.72%)
occurrences (all)	1	2	1
Cellulitis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Gingivitis			
subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	1 / 58 (1.72%)
occurrences (all)	0	2	1
Herpes simplex			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	2
Nasal herpes			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Paronychia			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Post-acute COVID-19 syndrome			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	1	1	1
Stenotrophomonas infection			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Tinea pedis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Chronic tonsillitis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	3	0	0
Tooth infection			

subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	1 / 58 (1.72%)
occurrences (all)	0	1	1
Viral pharyngitis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Vulvovaginal candidiasis			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Bacterial vaginosis			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Body tinea			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Tinea versicolour			
subjects affected / exposed	0 / 47 (0.00%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Diarrhoea infectious			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Gastroenteritis			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Influenza			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Lower respiratory tract infection			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Mastitis bacterial			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Nail infection			

subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Oesophageal candidiasis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Onychomycosis			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Otitis externa			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	3 / 47 (6.38%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	3	1	0
Pneumonia			
subjects affected / exposed	3 / 47 (6.38%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	3	1	0
Post procedural infection			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Ear infection			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Vulvovaginal mycotic infection			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection viral			

subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Postoperative wound infection			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Otitis media			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Hordeolum			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Fungal skin infection			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Folliculitis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Eye infection			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Diverticulitis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Coronavirus infection			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis viral			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Bacterial vulvovaginitis			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			

subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Localised infection			
subjects affected / exposed	0 / 47 (0.00%)	2 / 56 (3.57%)	0 / 58 (0.00%)
occurrences (all)	0	2	0
Herpes zoster			
subjects affected / exposed	0 / 47 (0.00%)	3 / 56 (5.36%)	0 / 58 (0.00%)
occurrences (all)	0	3	0
Otitis media chronic			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0
Klebsiella bacteraemia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Enterococcal bacteraemia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	2 / 58 (3.45%)
occurrences (all)	1	0	2
Hypercholesterolaemia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Hypokalaemia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Vitamin D deficiency			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	1 / 58 (1.72%)
occurrences (all)	1	0	1
Decreased appetite			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Dehydration			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0

Folate deficiency			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 47 (2.13%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	1	0	0
Hypoproteinaemia			
subjects affected / exposed	2 / 47 (4.26%)	0 / 56 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Iron deficiency			
subjects affected / exposed	1 / 47 (2.13%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	1	1	0
Hyperlipidaemia			
subjects affected / exposed	0 / 47 (0.00%)	1 / 56 (1.79%)	0 / 58 (0.00%)
occurrences (all)	0	1	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 July 2020	The main purpose of this amendment was to provide updated criteria and an updated definition for the End of Primary Treatment (EOPT), to establish the modified Full Analysis Set as the primary analysis set for efficacy endpoints, to add biweekly phone visits, to provide guidance on regional enrollment limits, and to provide further instruction on off-site visits, infusion reactions, and minor updates on the statistical analysis. and operational aspects of the protocol.
01 September 2021	The main purpose of this amendment was to allow a change in study drug formulation of ravulizumab during the Long-Term Extension Period, add visits to reflect the Treatment Period of up to 4.5 years, update the statistical methods, and incorporate administrative changes, as appropriate.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported